By Jamie Santo ( August 12, 2013, 9:57 PM EDT) -- A Trius Therapeutics Inc. shareholder brought a putative class action Friday aimed at stopping a buyout by Cubist Pharmaceuticals Inc. worth up to $818 million, calling the offer ill-timed and undervalued given the "imminent launch" of the drug developer's first product....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.